The University of Edinburgh
Edinburgh Neuroscience

CCBS
Centre for Clinical Brain Sciences

Professor Peter Horby, Professor Martin Landray
RECOVERY trial Co-chairs
Nuffield Department of Population Health
Oxford

14th January 2021

Dear Peter and Martin

RECOVERY trial DMC report

The RECOVERY trial DMC reviewed the safety and efficacy data that were available today for the 26,560 patients randomised. For the interventions still in active recruitment, the numbers included in the comparison of each agent with its control were respectively: convalescent plasma (10,406), tocilizumab (3,167), REGN-COV2 (3,408), aspirin (6,367) and colchicine (3,863).

For convalescent plasma, we saw no convincing evidence that further recruitment would provide conclusive proof of worthwhile mortality benefit either overall or in any pre-specified subgroup. We therefore recommend that recruitment to the convalescent plasma portion of the study should cease and follow-up be completed.

For all the other treatments under study in RECOVERY, in the light of the available trial data and all relevant external information (including the recent pre-print publication of the REMAP-CAP results for Tocilizumab and Sarilumab), we see no cogent reason to modify the protocol or intake to the study. For all these treatments, we therefore recommend continuing recruitment.

We recommend that the collection of the supplementary 72-hour safety forms for convalescent plasma and REGN-COV2 could now cease.

The DMC will next review the safety and efficacy data for all treatments on 21st January 2021.

Yours sincerely



Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO
Chairman RECOVERY trial DMC
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
t: +44 (0)131 465 9602 / w: www.ccbs.ed.ac.uk / e:Peter.sandercock@ed.ac.uk